Prevention of yellow fever in travellers: an update

Reno, Elaine; Quan, Nicolas G; Franco‐Paredes, Carlos; Chastain, Daniel B; Chauhan, Lakshmi; Rodríguez‐Morales, Alfonso J.; Henao‐Martínez, Andrés F.

doi:10.1016/s1473-3099(20)30170-5

Cited by 29 publications

(35 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have shown a large cohort of travelers who safely received the YF vaccine before travel. Since the rate of adverse events with the Yellow vaccine is of about three events per 100,000 doses [ 13 ], with our relatively small representative sample we cannot extrapolate a different safety profile. Nevertheless, through standardized travel advice encounters, we safely delivered the vaccine to more than 150 travelers aged 60 years or older, travelers with controlled HIV, and history of cancer, pregnancy, or heme-immune disorders not listed as absolute contraindications.…”

Section: Discussionmentioning

confidence: 99%

Ensuring the Safety of Yellow Fever Vaccination in Travelers—The Experience at a Large U.S. Academic Medical Center in Colorado

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Yellow fever (YF) virus has the potential to cause fatal outcomes among at-risk individuals visiting endemic areas. Vaccinating travelers who are at risk is necessary to prevent virus-related life-threatening complications. We lack data on the clinical features of persons seeking YF vaccination. We aim to describe the characteristics of a cohort of persons receiving the YF vaccine before travel. Methods: A retrospective analysis of 964 travelers receiving the YF vaccine (Stamaril®) from Oct 2016 to Jul 2019 was performed at the University of Colorado Hospital, U.S. Percentages, means, and standard deviations were calculated. A multivariate logistic regression model was built to evaluate the association between receiving YF vaccination less than 10 days before departure and visiting friends and relatives (VFR). Results: The average age of the subjects was 39 ± 18 years with a range of nine months to 83 years. Persons who were 60 years of age and older represented 17%. Women consisted of 52%, and most of the travelers were Caucasians (64%). Travelers reported traveling to Africa (57%) or South America (40%). The primary destinations for travelers overall were Kenya (19%), Uganda (11%), and Tanzania (11%) in Africa; and Peru (14%) and Brazil (13%) in South America. The most common reasons for travel included leisure (44%), VFR (18%), and mission trips (10%). Comorbidities included a history of hematologic disorders (4%), HIV infection (2%), and diabetes mellitus (3%). The average duration between vaccine administration and travel was 43 days. Those VFR were two times more likely to receive the YF vaccination <10 days before departure. Conclusions: Identifying the type of travel, itinerary, and underlying medical conditions allows providers to administer the YF vaccine to travelers safely. There is a need to identify strategies to improve the timing of YF vaccination among VFR travelers.

show abstract

Section: Discussionmentioning

confidence: 99%

Ensuring the Safety of Yellow Fever Vaccination in Travelers—The Experience at a Large U.S. Academic Medical Center in Colorado

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The best-known example of successful use of the IHR is vaccination against yellow fever (YF) which is mandatory for travellers to YF endemic countries and non-endemic countries with a potential for introducing YF virus ( Reno et al, 2020 ). The IHR allows for the addition of other vaccines (article 36 and Annex 6).…”

Section: Can the Vaccines Open International Travel?mentioning

confidence: 99%

COVID-19 vaccines under the International Health Regulations – We must use the WHO International Certificate of Vaccination or Prophylaxis

Petersen¹,

Lucey²,

Blumberg³

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

“…A highly effective vaccine (17D YF-VAX) has been used safely for decades in areas of transmission, both in Africa and tropical South America. Additionally, YF-VAX is a travel-required vaccine as part of the World Health Organization (WHO) International Health Regulations (IHR) [10].…”

mentioning

confidence: 99%

“…The occurrence of imported YF cases in South America could lead to potential urban outbreaks in various non-endemic areas due to geographic expansion of the vector, mostly favored by climate change [31]. This represents a challenge particularly for healthcare workers who should be kept up-to-date on the preventive measures and the changes in the levels of risk from tourism areas, which is variable and not always considered by travel medicine practitioners at the right time [10].…”

mentioning

confidence: 99%

Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic

Rodríguez‐Morales

Bonilla-Aldana

Suárez

et al. 2021

Travel Medicine and Infectious Disease

Self Cite

View full text Add to dashboard Cite

Prevention of yellow fever in travellers: an update

Cited by 29 publications

References 59 publications

Ensuring the Safety of Yellow Fever Vaccination in Travelers—The Experience at a Large U.S. Academic Medical Center in Colorado

Ensuring the Safety of Yellow Fever Vaccination in Travelers—The Experience at a Large U.S. Academic Medical Center in Colorado

COVID-19 vaccines under the International Health Regulations – We must use the WHO International Certificate of Vaccination or Prophylaxis

Yellow fever reemergence in Venezuela – Implications for international travelers and Latin American countries during the COVID-19 pandemic

Contact Info

Product

Resources

About